Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline)(Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline))

概要

基本信息

药物类型

预防性疫苗、结合疫苗

别名

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染其他疾病

在研适应症

伤寒

非在研适应症-

原研机构

GSK Plc

在研机构

GSK Plc

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline) 相关的临床试验

NCT05613205

/ Completed临床1期

A Phase 1, Observer-blind, Randomised, Controlled, Single-centre Study to Evaluate the Safety, Reactogenicity, and Immune Responses to an Adjuvanted and Non-adjuvanted Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults 18 to 50 Years of Age in Europe

A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK).
The purpose of this first-time-in-human study is to evaluate the safety and immunogenicity profile of a low and a full dose of the investigational vaccine, formulated with or without adjuvant, administered in 2 doses, 24 weeks apart, in healthy adults 18 to 50 years of age in Europe.

开始日期2022-11-28

申办/合作机构

GSK Plc

[+1]

100 项与 Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline) 相关的临床结果

登录后查看更多信息

100 项与 Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline) 相关的转化医学

登录后查看更多信息

100 项与 Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline) 相关的专利（医药）

登录后查看更多信息

100 项与 Typhoid and Paratyphoid A conjugate without adjuvant vaccine(GlaxoSmithKline) 相关的药物交易

登录后查看更多信息